291 related articles for article (PubMed ID: 23901283)
1. Current status of bevacizumab in advanced ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Panici PB; Venezia M; Tomao S
Onco Targets Ther; 2013; 6():889-99. PubMed ID: 23901283
[TBL] [Abstract][Full Text] [Related]
2. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
4. The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects.
Mao CL; Seow KM; Chen KH
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805914
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
9. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.
McClung EC; Wenham RM
Int J Womens Health; 2016; 8():59-75. PubMed ID: 27051317
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
11. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.
Davidson BA; Secord AA
Int J Womens Health; 2014; 6():289-300. PubMed ID: 24648773
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors for the treatment of ovarian cancer.
Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapies in ovarian cancer.
Reinthaller A
Memo; 2016; 9(3):139-143. PubMed ID: 27752291
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy for ovarian cancer.
Rosa DD; Clamp AR; Collinson F; Jayson GC
Curr Opin Oncol; 2007 Sep; 19(5):497-505. PubMed ID: 17762578
[TBL] [Abstract][Full Text] [Related]
15. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
16. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
Han ES; Lin P; Wakabayashi M
Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
[TBL] [Abstract][Full Text] [Related]
17. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
Itamochi H
World J Biol Chem; 2010 Jul; 1(7):209-20. PubMed ID: 21537476
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of bevacizumab in the treatment of ovarian cancer.
Yoshida H; Yabuno A; Fujiwara K
Drug Des Devel Ther; 2015; 9():2351-8. PubMed ID: 25960638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
